Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
The team that implanted the first TaurusTrio TAVR valve at Beijing An Zhen Hospital, Capital Medical University in July 2023.

Chinese made version of JenaValve TAVR device implanted in first patient

The first patient was enrolled in a multicenter clinical trial for the TaurusTrio transcatheter aortic valve replacement system, used for aortic regurgitation.

Abbott pulled the Trifecta GTaortic surgical valve off market in July 2023 after it was determined it had early structural valve deterioration (SVD) before 5 years.

Abbott pulls Trifecta heart valves off the market due to early deterioration

The FDA sent notice today that Abbott is pulling the Trifecta aortic surgical heart valve off the U.S. market due to the risk of early structural valve deterioration in less than 5 years. 

How depression, cognitive dysfunction impact long-term TAVR outcomes

Both conditions are fairly common in patients who undergo TAVR. Is this something cardiologists should be keeping in mind? 

the words "FDA recall" on a board

FDA announces recall of nearly 8,000 Impella blood pumps due to risk of injury or death in TAVR patients

There have been 30 complaints so far about this issue, including 26 injuries and four deaths.

Thumbnail

Abbott recalls delivery sheath for LAA occluder device after 16 injuries

The FDA has categorized this as a Class I recall, which means using the devices “may cause serious injuries or death.”

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

Atrial fibrillation after TAVR linked to much higher risk of death, heart failure

Researchers tracked data from nearly 7,000 TAVR patients for two years, focusing on all-cause mortality and heart failure hospitalizations.

Matt Martinez, MD, Morristown Medical Center HCM program, explains how hypertrophic cardiomyopathy patient management is changing.

Exercise plays a key part in HCM management

Matthew Martinez, MD, detailed the many ways HCM care management is changing during an exclusive interview at ASE 2023.

Thumbnail

Permanent pacemakers after TAVR: Tracking the impact of modern self-expanding valves

Researchers explored data from more than 3,000 TAVR patients, presenting their results in JACC: Cardiovascular Interventions. 

Displaying 241 - 248 of 2332

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup